Focused On-demand Library for Mucolipin-1

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Our library stands out due to several important features:

  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.







Alternative names:

MG-2; Mucolipidin; Transient receptor potential channel mucolipin 1

Alternative UPACC:

Q9GZU1; D6W647; Q7Z4F7; Q9H292; Q9H4B3; Q9H4B5


Mucolipin-1, also known as MG-2 or Transient receptor potential channel mucolipin 1, plays a pivotal role in cellular processes by acting as a nonselective cation channel. It is crucial for the regulation of membrane trafficking, metal homeostasis, and Ca(2+) release from lysosomal vesicles. This protein is involved in various lysosome-dependent cellular events, including organelle fusion, trafficking, exocytosis, and autophagy. Additionally, Mucolipin-1 is essential for macrophage phagocytosis and lactosylceramide trafficking, indicating its role in endocytic membrane fusion events. It also functions as a sensor for lysosomal active oxygen species, triggering autophagy and regulating mTORC1 signaling.

Therapeutic significance:

Mucolipin-1's association with Mucolipidosis 4, a severe lysosomal storage disorder, underscores its therapeutic significance. Understanding the role of Mucolipin-1 could open doors to potential therapeutic strategies for treating this debilitating condition by targeting the underlying genetic and biochemical pathways.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.